Temafloxacin voluntary withdrawal: concerns about multicenter testing and postmarketing surveillance

Ann Pharmacother. 1992 Jul-Aug;26(7-8):995. doi: 10.1177/106002809202600726.
No abstract available

Publication types

  • Editorial

MeSH terms

  • Anti-Infective Agents*
  • Clinical Trials as Topic
  • Drug Monitoring*
  • Fluoroquinolones*
  • Humans
  • Multicenter Studies as Topic
  • Product Surveillance, Postmarketing*
  • Quinolones / adverse effects*
  • United States
  • United States Food and Drug Administration

Substances

  • Anti-Infective Agents
  • Fluoroquinolones
  • Quinolones
  • temafloxacin